The HIV-1 reverse transcriptase mutants G190S and G190A, which confer resistance to non-nucleoside reverse transcriptase inhibitors, demonstrate reductions in RNase H activity and DNA synthesis from tRNA(Lys, 3) that correlate with reductions in replication efficiency

Virology
J WangLisa M Demeter

Abstract

We evaluated the replication efficiency of the HIV reverse transcriptase (RT) mutants K103N, G190A, and G190S, which confer resistance to the non-nucleoside RT inhibitor efavirenz, using growth competition assays in cell culture. In the absence of efavirenz, the fitness hierarchy was G190S < G190A < K103N < wild-type. The fitness reduction of G190S relative to K103N was less evident at high efavirenz concentrations, although K103N still replicated more efficiently. Efficiency of RNase H cleavage and RNA-dependent DNA synthesis from tRNA(Lys, 3) correlated with relative fitness, in biochemical studies of mutant RTs. Presteady state and steady state polymerization assays using DNA primers detected no abnormalities. This work is consistent with previous studies demonstrating that initiation of viral DNA synthesis is reduced in mutants with slowed RNase H cleavage, and suggests that both abnormalities contribute to the replication defect of these mutants. It also suggests that high concentrations of efavirenz are unlikely to favor the selection of G190S clinically.

References

Nov 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·V GopalakrishnanS J Benkovic
Apr 25, 1997·The Journal of Biological Chemistry·C PalaniappanR A Bambara
Aug 22, 2000·Antimicrobial Agents and Chemotherapy·L T BachelerK Abremski
Oct 18, 2000·Proceedings of the National Academy of Sciences of the United States of America·M WisniewskiR A Bambara
Nov 9, 2000·Journal of Virology·A F MaréeR J De Boer
Jul 4, 2001·The Journal of Biological Chemistry·M BalakrishnanR A Bambara
Aug 11, 2001·The New England Journal of Medicine·M A AlbrechtUNKNOWN AIDS Clinical Trials Group 364 Study Team
Jul 3, 2002·Proceedings of the National Academy of Sciences of the United States of America·John G JuliasStephen H Hughes
Jul 25, 2003·The Journal of Biological Chemistry·Yan ChenRobert A Bambara
Dec 12, 2003·The New England Journal of Medicine·Gregory K RobbinsUNKNOWN AIDS Clinical Trials Group 384 Team
Apr 30, 2004·The New England Journal of Medicine·Roy M GulickUNKNOWN AIDS Clinical Trials Group Study A5095 Team
Jun 9, 2004·The International Journal of Biochemistry & Cell Biology·Robert A Domaoal, Lisa M Demeter

❮ Previous
Next ❯

Citations

Aug 21, 2013·AIDS and Behavior·David J GrelottiMatthew J Mimiaga
Apr 1, 2011·Future Microbiology·Shiro Ibe, Wataru Sugiura
Mar 7, 2012·Future Virology·Denis R ChoperaZabrina L Brumme
Oct 16, 2007·Clinical Microbiology Reviews·Carrie Dykes, Lisa M Demeter
Sep 22, 2010·AIDS Research and Human Retroviruses·Michael A KolberRichard D Moore
May 1, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Viktor von WylUNKNOWN Swiss HIV Cohort Study
Feb 22, 2008·Virus Research·Javier Martinez-Picado, Miguel Angel Martínez
Feb 8, 2008·Virus Research·Truus E M Abbink, Ben Berkhout
Nov 21, 2007·Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases·Vladimir V LeontievLilach Hadany
Dec 31, 2019·Oxidative Medicine and Cellular Longevity·Ekaterina BayurovaMaria Isaguliants

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.